Korea United Pharm
033270 · KOSPI
Public Market Listing
033270KOSPI
Live quotes, historical charts, and market capitalization for Korea United Pharm are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
Cilostazol/rosuvastatin (UI022/UI023)No recent activity | Phase 3 | PDE3 (phosphodiesterase 3) and HMG-CoA reductaseSmall molecule | Atherosclerotic Cardiovascular Disease |
UIC201604No recent activity | Phase 1 | HMG-CoA reductaseSmall molecule | Atherosclerotic Cardiovascular Disease |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (1)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | $50M | — | — | — | report ↗ |
Annual history (2 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $203M | — | — | — | report ↗ |
Korea United Pharm reported revenue of $203.24M, down 4.2% YoY for fiscal year 2025.
Figures only: this period's report disclosed no narrative text
View 1 more year
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $212M | — | — | — | report ↗ |